Bristol-Myers Squibb Corporation will pay to settle allegations. The amount of money spent was estimated at $19.5 million. This agency had misled medical staff about the dangers of the Abilify drug and had also wrongfully promoted this anti-psychotic pill. This decision was taken on December 8th by the California Attorney General Kamala Harris.
Harris announced the settlement of a lawsuit which implied the violation of the state business code. On the same day, a court from San Diego has sent their final agreement concerning this matter. Nevertheless, despite all accusations, Bristol-Myres Squibb Corporation based in New York had denied any misconduct, but representatives of the agency agreed upon the existence of different marketing restraints.
Otsuka America Pharmaceutical, Inc. is the company which produced Abilify drug. In a recent statement, a spokesperson from Bristol-Myers Squibb Corp. has declared that their agency has not commercialized this medication since 2013. The representative stated that its company would gladly put this problem aside to concentrate on what matters. Their goal is to manufacture transformational drugs bound to help patients suffering from severe illnesses.
The lawsuit emerged from an investigation conducted by California officials, the District of Colombia, but also other 42 countries which declared the commercialization of Abilify drug for presumably off-label purposes. The US Food and Drug Administration has approved Abilify as a treatment meant to cure schizophrenia, Tourette’s illness, major depressive disorders and bipolar disorder for both children and adults. Back in 2014, the sales were estimated to reach approximately $5.5 billion.
Authorities from California had testified that Bristol-Myres Squibb advertised the Abilify drug for unapproved purposes for elderly patients who suffered from dementia and children. A medication guide from Otsuka approved by the FDA claimed that pills like Abilify could increase the risk of death for senior patients with psychosis related to dementia. What is more, this medicine may fuel suicidal actions and thoughts in children.
Based on the information provided by Harris in her statement, besides the stimulated sales representatives engaging in off-label marketing, the investigation revealed that the agency deceived doctors, medical staff and patients about the risks implied by the dangerous drug. They were not informed about the side effects that could have occurred after taking the pill. They had also wrongfully represented the discoveries of scientific research concerning this medicine.
Image courtesy of: wikipedia